{"id":"W4220707985","doi":"10.1158/1538-7445.sabcs21-ot2-24-02","title":"Abstract OT2-24-02: ZEST: Randomized phase III study evaluating efficacy and safety of niraparib in patients with HER2-negative BRCA-mutated or triple-negative breast cancer with detectable circulating tumor DNA after definitive therapy","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; Breast cancer; Triple-negative breast cancer; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00151723,0.001364575,0.002169312,0.0003526134,0.0003328361,0.001137496,0.0009384092,0.001428178,0.00764318],"category_scores_gemma":[0.001367474,0.0006132533,0.001268549,0.0004855329,0.001288977,0.001111303,0.0003402811,0.003021772,0.0011887],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008072674,"about_ca_system_score_gemma":0.001539182,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009975928,"about_ca_topic_score_gemma":0.002445044,"domain_scores_codex":[0.9995543,0.0002628343,0.00001911221,0.00005869405,0.00003430643,0.00007072775],"domain_scores_gemma":[0.9992486,0.0001921159,0.0001504727,0.00006222862,0.00005102912,0.000295591],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9657855,0.009160578,0.001119003,0.0006042232,0.0006334968,0.00006177231,0.00005604204,0.0005993018,0.006552963,0.0001197086,0.001535302,0.01377208],"study_design_scores_gemma":[0.9257689,0.07100779,0.001576139,0.00001806895,0.000174713,0.00004614829,0.0000151678,0.0003486568,0.0004018494,0.00008720012,0.0005451381,0.00001030052],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9859534,0.002350795,0.0007272185,0.0005906606,0.000214932,0.005526267,0.002422257,0.000191918,0.002022482],"genre_scores_gemma":[0.9814134,0.002018169,0.001643374,0.001200331,0.0002266607,0.005973627,0.003060086,0.00004999735,0.004414456],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00764318,"threshold_uncertainty_score":0.02556902,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07882265798531476,"score_gpt":0.4216131597799296,"score_spread":0.3427905017946149,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}